Cyclerion Therapeutics faces a precarious financial outlook characterized by a lack of sustainable revenue, as evidenced by the 100% revenue contraction in 2026Q1. The company's reliance on sporadic milestone payments to fund its sGC stimulator pipeline is ins...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 4, 2026 | -$0.41+94.2% vs -$7.10 | — vs $2M |
Q2 2026 May 12, 2026 | -$0.76+95.6% vs -$17.20 | — vs — |
Q2 2026 Mar 30, 2026 | -$0.19+50.0% vs -$0.38 | $100,000+0.0% vs $100,000 |
Q2 2026 Mar 25, 2026 | -$0.38+0.0% vs -$0.38 | $100,000+0.0% vs $100,000 |
Advancing lead program KRSA-028 toward the clinic, with Phase 1 healthy volunteer data expected mid-2027 and interim proof-of-concept data in Alzheimer's patients anticipated by year-end 2027 or first quarter of 2028
Benchmark CYCN against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Cyclerion Therapeutics, Inc. (CYCN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $23.52 | $15.73M | -3.08 | 3.7% | -170.11% | -39.34% | — | |
| $9.70 | $2.25B | 16.17 | 19.63% | 32.98% | 39.59% | — | |
| $34.54 | $7.13B | -12.47 | — | -7585.86% | -69.59% | — | |
| $0.56 | $10.83M | -0.17 | — | — | -187.45% | — | |
| $8.68 | $454.43M | -1.92 | -92.84% | -80.67% | -14.98% | — | |
| $3.34 | $1.07B | 167.00 | 22.23% | -11.08% | — | — |
Cyclerion Therapeutics, Inc. (CYCN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Cyclerion Therapeutics, Inc. (CYCN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Apr 1, 2026·SEC
Feb 17, 2026·SEC
Jan 6, 2026·SEC
Get notified when CYCN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Cyclerion Therapeutics, Inc. (CYCN) stock FAQ — growth, dividends, profitability & financials explained
Cyclerion Therapeutics, Inc. (CYCN) reported $1.9M in revenue for fiscal year 2025.
Cyclerion Therapeutics, Inc. (CYCN) grew revenue by 3.7% over the past year. Growth has been modest.
Cyclerion Therapeutics, Inc. (CYCN) reported a net loss of $6.7M for fiscal year 2025.
Cyclerion Therapeutics, Inc. (CYCN) has a return on equity (ROE) of -39.3%. Negative ROE indicates the company is unprofitable.
Cyclerion Therapeutics, Inc. (CYCN) had negative free cash flow of $4.5M in fiscal year 2025, likely due to heavy capital investments.
